ライフサイエンスコーパス: vs

1 vey (median score, 0 in the sertraline group vs 0 in the placebo group; between-group difference, 0 [

2 d an ASCVD event (0.390; 95% CI, 0.312-0.467 vs 0.08; 95% CI -0.001 to 0.181) and to result in more a

3 but statistically significant (0.2 [SD 1.1] vs 0.1 [1.1], p=0.010) difference between the two groups

4 int visual disturbance score improved by 3.2 vs 0.1 in the sham group (difference, -3.0; 95% CI, -4.3

5 +/- standard deviation, 0.09 mL/mL +/- 0.03 vs 0.11 mL/mL +/- 0.03, respectively; P = .007).

6 with the placebo group (0.149 mean episodes vs 0.146 mean episodes; p=0.522).

7 MCPP cases than controls (median, 4.0 x 103 vs 0.19 x 103 copies/mL), but overlapped substantially (

8 ec), or fractional anisotropy (0.43 +/- 0.05 vs 0.42 +/- 0.06).

9 The mean (SD) SMR was 0.46 (1.06) vs 0.50 (1.50) events per year in the every 4 weeks vs e

10 otrauma incidence (0% in the intensive group vs 0.6% in the moderate group; absolute difference, -0.6

11 or alone compared with clopidogrel-GPI (0.3% vs 0.7%; OR, 0.43; 95% CI, 0.11-1.66).

12 ised towns: 1.13, SMR 0.83, 95% CI 0.77-0.88 vs 0.73, 0.69-0.77, respectively) and from 1999 to 2006

13 atients below or above the median risk (0.77 vs 0.75; P = .92).

14 and from 1999 to 2006 (1.15, 0.91, 0.86-0.97 vs 0.79, 0.75-0.84).

15 eviation, [0.89 +/- 0.09] x 10(-3) mm(2)/sec vs [0.9 +/- 0.09] x 10(-3) mm(2)/sec), or fractional ani

16 ed to T2DM subjects (0.037 +/- 0.004 mum(-2) vs. 0.023 +/- 0.003 mum(-2) , P = 0.024) that were non-s

17 and slightly worse postoperative BCVA (0.06 vs. 0.03 logMAR, P = 0.039).

18 in the supplement group [43.85 +/- 18.98 mm vs. 0.05 +/- 9.57 mm shift; effect size: 2.9; F(1,39) =

19 -significantly smaller (0.27 +/- 0.01 mum(2) vs. 0.32 +/- 0.02 mum(2) , P = 0.197, Trained vs. T2DM).

20 eyes had worse mean preoperative BCVA (0.55 vs. 0.36 logarithm of the minimum angle of resolution (l

21 nt than did placebo (decrease of 2.02+/-2.32 vs. 0.56+/-1.39 ng per milliliter, P=0.02).

22 ity (intraclass correlation coefficient=0.66 vs. 0.61); convergent validity (r with comprehensive mea

23 inued access registry, both at 30 days (8.2% vs. 0.7%, respectively; p = 0.0001) and at 1 year (19.7%

24 alue(66% vs. 50%) and area under curve (0.81 vs. 0.70) improved significantly (P < 0.05) with SAFIRE.

25 nsistency reliability (Cronbach's alpha=0.81 vs. 0.88); test-retest reliability (intraclass correlati

26 t group (2-year cumulative event rates, 3.5% vs. 0.9%; hazard ratio, 3.87; 95% CI, 1.78 to 8.42; P<0.

27 he curve (AUC) was 0.984 for DCEMRI+HB phase vs. 0.934 for DCEMRI (p<0.68) and 0.852 for DCECT (p<0.0

28 r mean BCVA improvement after surgery (-0.50 vs. -0.32 logMAR, P < 0.001), and slightly worse postope

29 ht reduction with tolvaptan (-2.4 +/- 2.1 kg vs. -0.9 +/- 1.8 kg; p < 0.001).

30 lack Caribbean and 2 [1-5] for black African vs 1 [1-2] for white British), and although black Caribb

31 nts had more renal vascular thromboses (4.4% vs 1.3% tx alone, 0% pre; P = 0.04).

32 21.7%; P > .99), and 90-day mortality (3.3% vs 1.3%; P = .38).

33 nder room air conditions only (0.99 +/- 0.04 vs. 1.00 +/- 0.02; P < 0.05).

34 in II group than in the placebo group (-1.75 vs. -1.28, P=0.01).

35 on of diabetes (10 years [range, 1-25 years] vs 10 years [range, 2-26 years]), and mean body mass ind

36 Hospital mortality was similar (12.4% vs 10.3%; p = 0.635).

37 ond (median, 3.5 vs 9), and third (median, 0 vs 10.5) assessments (all p < 0.001).

38 e likely to have commercial insurance (19.6% vs 10.6%; p < 0.001) than those who were seen initially

39 men (total, 12.2 vs 17.6; first or last, 6.8 vs 10.7; P < .001 for both comparisons).

40 al stay for the moderate group was 12.4 days vs 10.9 days in the intensive group (absolute difference

41 and the key secondary end point (816 [5.9%] vs. 1013 [7.4%]; hazard ratio, 0.80; 95% CI, 0.73 to 0.8

42 less hands-on time (mean +/- SD) (87 +/- 41 vs 109 +/- 33 s; p = 0.037) and a longer delay before th

43 c death (15 [1.4%] for the bivalirudin group vs 11 [1.0%] for the control group; RR, 1.39; 95% CI, 0.

44 d lower rates of cross-over to resection (5% vs 11%; P< 0.0001) and development of carcinoma (1% vs 3

45 nged air leakage (7.8% in the FOREseal group vs 11.3% in the control group, P = 0.264) and the averag

46 on of taxa at higher vs. lower latitudes (8% vs. 11% of genera), despite 11-fold lower abundance (1.2

47 nera), despite 11-fold lower abundance (1.2% vs. 12.7% of basal area).

48 ss more than 300 genes in all patients (7.1% vs. 128%; P < 0.001).

49 individuals with more severe TBI (GCS, </=12 vs 13-15).

50 an clinically diagnosed cases (48/77 (62.3%) vs 13/41 (31.7%), p < 0.001).

51 35) and the composite outcome (1680 [12.2%]) vs 1383 [10.1%]; % absolute RD, 2.16; 95% CI, 1.43-2.89)

52 black Caribbean and 38.9% for black African vs 14.8% for white British), these differences were not

53 62-0.888; P = .007), with median PFS of 20.6 vs 15.6 months.

54 ighest quintile hospitals was $2160 ($12,960 vs $15,120; P < 0.005).

55 the primary end point (1344 patients [9.8%] vs. 1563 patients [11.3%]; hazard ratio, 0.85; 95% confi

56 o 1.36; 95% CI 1.04-1.78; adjusted rates 20% vs 16%; P = 0.023), more readmissions (odds ratio 1.57;

57 emission with full hematologic recovery (34% vs. 16%, P<0.001) and with respect to complete remission

58 anial aneurysm (53.8%) had a smoking history vs 163 of 564 patients without intracranial aneurysm (28

59 on average, than did patients with EPP (3574 vs 1669 microg/dL; P < .001).

60 st author publications than men (total, 12.2 vs 17.6; first or last, 6.8 vs 10.7; P < .001 for both c

61 ril and placebo groups (162.1 +/- 70.5 mm(3) vs. 177.3 +/- 94.3 mm(3), respectively; p = 0.73).

62 the 170-mug group became nonreactive to CPT vs 18% in the placebo group.

63 oscopy times were similar (21.2 min for FUSE vs 19.1 min for FVC; P = .32), but withdrawal time was s

64 (IQR, 1.0-2.0) pulmonary complications score vs 2.1 (95% CI, 2.0-2.3) and 2.0 (IQR, 1.5-3.0) for the

65 cantly reduced by flecainide (0 [range, 0-2] vs 2.5 [range, 0-4] for placebo; P < .01), with complete

66 taxel (median 4.07 months [95% CI 2.96-4.47] vs 2.76 months [2.60-2.96]; hazard ratio [HR] 0.757, 95%

67 likely to have a longer hospital stay (2.9 d vs. 2.5 d, P <0.001) and were more likely to be discharg

68 ischarged to a rehabilitation facility (3.6% vs. 2.5%, P <0.001), adjusting for covariates.

69 xperienced similar rates of cyst growth (19% vs. 20%; P= 0.95) and lower rates of cross-over to resec

70 cy end point: in trial A, 188 of 254 (74.0%) vs 21 of 254 (8.3%; P < .001), for a difference in propo

71 .5 days; P = .31), 30-day readmission (22.4% vs 21.7%; P > .99), and 90-day mortality (3.3% vs 1.3%;

72 l eyes in both the superficial (17.68 mm(-1) vs. 21.55 mm(-1); P < 0.001) and deep (21.19 mm(-1) vs.

73 27 (46.6%) patients treated with ruxolitinib vs 23 (44.2%) with BAT (P = .40).

74 complications (Accordion grade >/=3, 23.05% vs 23.7%; P > .99), hospital stay (median: 8 vs 8.5 days

75 iders compared with all other providers (38% vs. 23% by volume, P < 0.001; 79% vs. 56% by total cost,

76 rval (CI) 2.8%-15.6%; adjusted means $26,604 vs $24,263; P = 0.005), 12.4% longer length of stay (95%

77 gressive elevations in ICP (supine, 15 +/- 2 vs. 24 h head-down tilt, 15 +/- 4 mmHg).

78 55 mm(-1); P < 0.001) and deep (21.19 mm(-1) vs. 24.38 mm(-1); P < 0.001) networks.

79 increased in the SA CMC group (31.2 +/- 1.0% vs. 24.7 +/- 2.2% in vehicle-treated mice; p < 0.05) but

80 4%-72.1%) and in trial B, 192 of 255 (75.3%) vs 25 of 260 (9.6%; P < .001), for a difference in propo

81 ial, or incomplete hematologic recovery (44% vs. 25%, P<0.001).

82 versus MI not related to a stented site (59% vs. 26%, p = 0.001).

83 601 were classified as having high BPE (71% vs 29%, respectively; P < .001).

84 dex (31.4 kg/m(2) [range, 24.7-48.1 kg/m(2)] vs 29.8 kg/m(2) [range, 22.9-44.0 kg/m(2)]) were not sig

85 7; P = .04) but not with heparin plus GPI (0 vs 3 [0.3%]; P = .30).

86 d to a rehabilitation facility after LT (22% vs 3%) and be rehospitalized within the first posttransp

87 P< 0.0001) and development of carcinoma (1% vs 3%; P= 0.008).

88 )-TOC than (64)Cu-DA(IR800)-TOC (5.2 +/- 0.2 vs. 3.6 +/- 0.4 percentage injected dose per gram).

89 rence between PB-type cancers and PDAC (33.3 vs 31.4 months, P = .66).

90 ect a substantially lower response rate (21% vs. 31% and 49%, respectively) and an aging workforce th

91 p=0.0034) and less time hyperglycaemic (27% vs 32%; p=0.0279) than did pregnant control participants

92 for which the search process is long ( 1 min vs. 33 min).

93 d remission in 51.5% of patients given Cx601 vs 35.6% of controls, for a difference of 15.8 percentag

94 the group that received RVD alone (50 months vs. 36 months; adjusted hazard ratio for disease progres

95 gher for those with CNS complications (75.8% vs 37.8%; p < 0.001) and varied by type of CNS injury; m

96 l versus Prograf using observed values (47.7 vs 38.6 mL/min per 1.73 m, P < 0.001) and was superior b

97 21 control) and time spent hypoglycaemic (3% vs 4%; p=0.10).

98 pital mortality (2.5% in the intensive group vs 4.9% in the moderate group; absolute difference, -2.4

99 ost 2-fold better fit to the data (R2 = 9.2% vs 4.9%).

100 ediate I prognostic risk AML (EFS, 26% +/- 4 vs 40% +/- 5 at 4 years; Cox P = .002) and for the inter

101 internal-tandem duplications (EFS, 18% +/- 5 vs 40% +/- 7; Cox P < .001).

102 e control group (31 [33%] of 94 participants vs 42 [49%] of 86 participants, respectively, adjusted o

103 ents who did not receive anticoagulants (71% vs 42%, respectively; P < .0001).

104 tter, 100% vs 76% gained >/=1 lines, and 59% vs 43% were within +/-0.13 D spherical equivalent.

105 significant differences in 5-year OS (36.7% vs. 44.6%, p = 0.4289) or 5-year LTP (73.3% vs. 67.9%, p

106 de 300 contrast media groups (469 HU +/- 167 vs 447 HU +/- 166, respectively [P = .241]; 95% confiden

107 black Caribbean and 21.9% for black African vs 47.4% for white British) and the number of partners i

108 c death (44 [4.0%] for the bivalirudin group vs 48 [4.3%] for the control group; RR, 0.93; 95% CI, 0.

109 ent age was 62.1 (20.3) years for ambulatory vs 48.1 (22.3) years for diplopia-related ED visits.

110 h SCT when defined using HbA1c values (29.2% vs 48.6% for prediabetes and 3.8% vs 7.3% for diabetes i

111 stay (95% CI 2.3%-23.5%; adjusted means 5.9 vs 5.2 days; P = 0.015), more complications (odds ratio

112 re similar between groups (6.4 +/- 2.3 mm Hg vs. 5.8 +/- 2.7 mm Hg; p = 0.17), whereas the ViR group

113 a cutoff, 104 patients (22%; 54 azithromycin vs 50 placebo) had experienced an airflow decline; 138 p

114 r adsorbent recirculating system group (9.5% vs 50.0% with standard medical treatment; p = 0.004), es

115 (82% vs. 62%), positive predictive value(66% vs. 50%) and area under curve (0.81 vs. 0.70) improved s

116 At 12 months, 61% vs 53% had UDCVA of 20/25 or better, 100% vs 76% gained

117 ad lower incidence of relapse at 1 year (15% vs 54%, P = 0.05).

118 entricular ejection fraction (45.6 +/- 17.4% vs. 55.3 +/- 11.1%; p < 0.001).

119 iders (38% vs. 23% by volume, P < 0.001; 79% vs. 56% by total cost, P < 0.001).

120 n sustaining an injury than men (868 [27.1%] vs 562 [23.7%]; P = .01).

121 ed within the first posttransplant year (78% vs 57%), all P < .001.

122 s (81% vs 61%, P = .20) or at 18 months (67% vs 58%, P = .74).

123 se effect was decreased blood calcium (68.9% vs 59.8%).

124 ce of relapse/nonresponse (CIR/NR; 6% +/- 3% vs 6% +/- 2%; PGray = .03) did not significantly differ

125 o 1.57; 95% CI 1.08-2.29; adjusted rates 10% vs 6%; P = 0.018), and no difference in discharge destin

126 ic group than in the nonhemorrhagic group (1 vs 6.5; P < .001).

127 tral regurgitation moderate or higher (19.4% vs. 6.8%; p = 0.003).

128 ne; 138 patients (30%) died (78 azithromycin vs 60 placebo).

129 DPN, mean age (60 years [range, 38-79 years] vs 61 years [range, 46-75 years], respectively), mean du

130 not significantly different at 6 months (81% vs 61%, P = .20) or at 18 months (67% vs 58%, P = .74).

131 ant CGM users spent more time in target (68% vs 61%; p=0.0034) and less time hyperglycaemic (27% vs 3

132 er stents (</=3 mm; n = 95), specificity(82% vs. 62%), positive predictive value(66% vs. 50%) and are

133 of the occurrence of any complication (73.7% vs 66.4%; P = .21), severe complications (Accordion grad

134 vs. 44.6%, p = 0.4289) or 5-year LTP (73.3% vs. 67.9%, p = 0.8897) between CT-RFA and L-RFA.

135 sult was significantly more sensitive (97.6% vs 68.7%, P < .001) for the detection of severe malaria

136 D: 38.5 vs 86.0 months, P = 0.15 [BOS]; 60.5 vs 69.5 months, P = 0.80 [RAS]).

137 SV were listed primary diagnoses in 56 (30%) vs 7 (6%), respectively (P < .0001).

138 longer procedures with bivalirudin (7 [2.1%] vs 7 [0.7%]; relative risk, 2.87; 95% CI, 1.01-8.17; P =

139 te aminotransferase 0 hour, 15.6 +/- 9.3 U/L vs 7 hours, 24.8 +/- 14.6 U/L, P = 0.298).

140 ues (29.2% vs 48.6% for prediabetes and 3.8% vs 7.3% for diabetes in 572 observations from participan

141 irst 14 days were arm pain (57.4% [27 of 47] vs 7.4% [seven of 94]) and local tenderness (59.6% [28 o

142 the start of chest compressions (109 +/- 77 vs 70 +/- 56 s; p = 0.038).

143 le sepsis volume hospital were younger (64.7 vs 72.7 yr; p < 0.001) and were more likely to have comm

144 us spp morphotypes and those without (70.48% vs 74.08%; pinteraction=0.86).

145 ted in 70% hypertonic glucose (HG) (group 1) vs 75% HG alone (group 2).

146 12 cycles of attempt (70% [95% CI, 54%-80%] vs 76% [95% CI, 72%-80%], respectively).

147 1% vs 53% had UDCVA of 20/25 or better, 100% vs 76% gained >/=1 lines, and 59% vs 43% were within +/-

148 e without these morphotypes (efficacy 68.62% vs 76.72%; pinteraction=0.652); or between those with La

149 he periphery than in the posterior pole (46% vs. 76%) and negligible in controls.

150 higher risk of 30-day mortality (898 [6.5%] vs 790 [5.8%]; % absolute RD, 0.79; 95% CI, 0.23-1.35) a

151 vs 23.7%; P > .99), hospital stay (median: 8 vs 8.5 days; P = .31), 30-day readmission (22.4% vs 21.7

152 94]) and local tenderness (59.6% [28 of 47] vs 8.5% [eight of 94]).

153 similar among IHO workers and CR adults (12% vs. 8%; aPR: 1.14; 95% CI: 0.56, 2.29).

154 toring group) in France and $11,965 ($93,795 vs. $81,829) in the United States.

155 lung transplantation (low vs high LVD: 38.5 vs 86.0 months, P = 0.15 [BOS]; 60.5 vs 69.5 months, P =

156 87,476 in the gold-standard monitoring group vs. $86,829 in the real-life monitoring group) in France

157 hs or more after diagnosis of breast cancer, vs 87.5% (95% CI, 86.5%-88.4%) for women with no pregnan

158 = .64), event-free survival (EFS; 87% +/- 3% vs 89% +/- 4%; Plog-rank = .71), and cumulative incidenc

159 irst (median, 0 vs 9.5), second (median, 3.5 vs 9), and third (median, 0 vs 10.5) assessments (all p

160 m than those without at the first (median, 0 vs 9.5), second (median, 3.5 vs 9), and third (median, 0

161 survival was 13.8 months [95% CI 11.8-15.7] vs 9.6 months [8.6-11.2]; hazard ratio [HR] 0.73 [95% CI

162 21-0.918; P = .021), with median PFS of 21.4 vs 9.7 months; in standard-risk patients, HR was 0.640 (

163 spectively; p = 0.0001) and at 1 year (19.7% vs. 9.8%, respectively; p = 0.006).

164 Still, 5-year overall survival (89% +/- 3% vs 90% +/- 4%; Plog-rank = .64), event-free survival (EF

165 marginally improved with IS specimens (96.2% vs 92.4% for NP/OP specimens for all viruses combined [P

166 ns for all viruses combined [P = .41]; 96.9% vs 93.3% for all bacteria combined [P = .01]).

167 (vs cervical) anastomosis and a thoracotomy (vs absence) have previously been associated with increas

168 sed in CD in the abstinence/saline condition vs acute cocaine and HC.

169 Comparisons of cells from wild-type vs. AE3(-/-) mice show that AE3 (present in hippocampal

170 -OH/Fe(II)-OH2 reduction potential of 680 mV vs Ag/AgCl at pH 5.2.

171 oducible formal potentials of -157 +/- 2 mV (vs Ag/AgCl/3 M KCl) were observed, and the solid-contact

172 ed potential spectrum (between -1V and +0.5V vs. Ag/AgCl).

173 ility of coronary artery calcium (CAC) score vs age for incident ASCVD and how risk prediction change

174 the hymen), and delivery method (any vaginal vs all caesarean sections).

175 10 x 10(9) platelets per L) and disease (MDS vs AML).

176 antiplatelet treatment (aspirin/clopidogrel vs aspirin/placebo; double-blinded).

177 deliveries), prolapse stage (above the hymen vs at or beyond the hymen), and delivery method (any vag

178 pients needing full assistance (KPS 10%-40%) vs being independent (KPS 80%-100%) were more likely to

179 nomolar beta1-AR affinity >500-fold beta1-AR vs beta2-AR selectivity and no agonism.

180 ent opioid agonist treatments (eg, methadone vs buprenorphine) associated with differences in efficac

181 nificantly augmented cardiac apoptosis in WT vs. CD-WT mice, which was prevented by co-treatment with

182 DP ratio increases the incorporation of Shs1 vs Cdc11, which alters the curvature of filamentous sept

183 more direct topography involving bed nucleus vs central nucleus divisions; (2) CRF content of the CEA

184 Intrathoracic (vs cervical) anastomosis and a thoracotomy (vs absence)

185 Mental status (normal vs. delirium vs. coma) was assessed daily with the Confusion Assessme

186 and goal setting mediated the effect of LOW vs CONTROL (50%).

187 roup differences (individuals with addiction vs control individuals) in reward-related brain activati

188 accuracy for patients with AD with dementia vs controls (area under the receiver operating character

189 layers to surface; IQR, 8.0-16.9; P = .0098 vs controls).

190 om patients with inflammatory bowel diseases vs controls, we found that reactivity to intestinal bact

191 (27.9 +/- 9 nmol x min(-1) x g(-1), P < 0.05 vs. controls) and high-dose subgroups (37.2 +/- 7.8 nmol

192 7.2 +/- 7.8 nmol x min(-1) x g(-1), P < 0.01 vs. controls, P < 0.05 vs. standard-dose).

193 paring data for never vs ever smokers, never vs current smokers, and never vs former smokers.

194 determine if earlier or immediate treatment vs delayed or no surgical treatment improves patient out

195 Mental status (normal vs. delirium vs. coma) was assessed daily with the Confu

196 6 months was Roux-en-Y hepaticojejunostomy (vs duct-to-duct) (odds ratio, 3.06; 95% confidence inter

197 We focused on the ventral striatum (VS), due to its association with incentive motivation.

198 mutation status (e.g., EGFR-positive [EGFR+] vs. EGFR-negative) was assessed using the Wilcoxon rank-

199 layers to surface; IQR, 1.5-13.3; P < .0001 vs ERD, BE, and controls) and proximal (median, 5.0 cell

200 D and UC combined), comparing data for never vs ever smokers, never vs current smokers, and never vs

201 (1.50) events per year in the every 4 weeks vs every 12 weeks groups (P = .85).

202 tients administered belatacept every 8 weeks vs every 4 weeks.

203 on, which have distinct selectivity (feature vs. eye of origin) and dynamics (relatively slow vs. rel

204 er among former smokers (for fourth quartile vs. first quartile, odds ratio (OR) = 2.70, 95% confiden

205 g to the route of allergen exposure (inhaled vs food allergens).

206 smokers, never vs current smokers, and never vs former smokers.

207 [4%] vs two [2%]), and neutropenia (ten [5%] vs four [4%]).

208 ter depths, habitat features (i.e., brackish vs. freshwaters), and nucleic acids (DNA vs. RNA), sugge

209 and mean (SD) mBESS score (boys, 1.21 [1.5] vs girls, 0.71 [1.0]; mean difference, 0.50 [95% CI, 0.2

210 ted by the child (severity: boys, 15.1 [9.8] vs girls, 11.8 [9.2]; mean difference, 3.31 [95% CI, 1.6

211 ean (SD) total SAC-C score (boys, 23.9 [3.9] vs girls, 24.9 [3.5]; mean difference, -0.92 [95% CI, -1

212 ed by the parent (severity: boys, 11.1 [7.7] vs girls, 9.4 [8.1]; mean difference, 1.63 [95% CI, 0.21

213 iptin treatment increased the relative GLP-1 vs glucagon production in both non-diabetic and diabetic

214 platelet count (<10 x 10(9) platelets per L vs >/=10 x 10(9) platelets per L) and disease (MDS vs AM

215 in MI risk between patients who started PPIs vs H2RAs for the first 12 months, either in the commerci

216 t of BOS or RAS in lung transplantation (low vs high LVD: 38.5 vs 86.0 months, P = 0.15 [BOS]; 60.5 v

217 We compared steatosis estimates by PDFF vs histology.

218 in tear washes of patients with ocular graft-vs-host disease (oGVHD).

219 ent on the level of maturation (depolarizing vs. hyperpolarizing) of postsynaptic GABAA receptor acti

220 n the transactivation functions of AR and AR-Vs important for various physiological and disease proce

221 The respective role of UH vs. individual stochasticity varies greatly among demogr

222 is puts a strong constraint on preindustrial vs. industrial-era LUC emissions and suggests that upper

223 ndication and type of guidance (confirmatory vs. influential).

224 of population prevalence of chronic shedding vs. intensity and duration of chronic shedding in indivi

225 Adjusting for farm type (broiler vs. layer), the odds of resistance (although not statist

226 (DEGs) were found in LD vs MD, LE vs ME, LE vs LD, or ME vs MD comparisons.

227 Compared with controls, monkeys with VS lesions had deficits in learning to select rewarding

228 ce of rhesus macaques with ventral striatum (VS) lesions on a two-arm bandit task that had randomly i

229 erall population, nor in the colon (FFT: 23% vs LFT: 19%, P = 0.636) or rectal (FFT: 44% vs LFT: 35%,

230 any difference between the groups (FFT: 35% vs LFT: 29%, P = 0.290), neither regarding the overall p

231 vs LFT: 19%, P = 0.636) or rectal (FFT: 44% vs LFT: 35%, P = 0.330) cancer subgroups.

232 re treated with intramedullary nail fixation vs locking plate fixation.

233 HIGH SFM+ vs LOW SFM+ (CONTROL matched the dose of LOW).

234 High vs. low daily FA intake was dichotomized at 800mug (medi

235 slightly smaller fraction of taxa at higher vs. lower latitudes (8% vs. 11% of genera), despite 11-f

236 diabetes diagnosis (net worth of >/=$500000 vs <$25000: HR, 1.50; 95% CI, 1.34-1.68).

237 vels of systolic blood pressure (130-149mmHg vs <130mmHg; open label) and to antiplatelet treatment (

238 of water with higher THMs (>95th percentile vs.<25th percentile) and bladder cancer.

239 found in LD vs MD, LE vs ME, LE vs LD, or ME vs MD comparisons.

240 ally expressed genes (DEGs) were found in LD vs MD, LE vs ME, LE vs LD, or ME vs MD comparisons.

241 ssed genes (DEGs) were found in LD vs MD, LE vs ME, LE vs LD, or ME vs MD comparisons.

242 an, 5.0 cell layers to surface; IQR, 2.5-9.3 vs median 10.4 cell layers to surface; IQR, 8.0-16.9; P

243 vioral shifts in the salience of cocaine now vs money later, we found that ketamine, as compared to t

244 s minimised by centre, parity (three or less vs more than three deliveries), prolapse stage (above th

245 atified by treatment experience (experienced vs naive) and included block randomisation at nurse leve

246 eduction to CO in tetrahydrofuran at -0.48 V vs NHE, the least negative potential reported for a mole

247 34) after androgen deprivation therapy (ADT) vs no ADT and 1.21 (95% CI, 1.00-1.46) after orchiectomy

248 tality was 1.57 (95% CI, 1.04-2.39) after GH vs no GH.

249 d 1.21 (95% CI, 1.00-1.46) after orchiectomy vs no orchiectomy.

250 0, 1.09), skin tanning ability (for dark tan vs. no tan, multivariable-adjusted RR = 0.98, 95% CI: 0.

251 ariables, the difference in LOS for Medicaid vs non-Medicaid recipients varied significantly by state

252 with greater LTL attrition (3 herpesviruses vs none, beta = -0.07 and P = .02; 4 infections vs none,

253 none, beta = -0.07 and P = .02; 4 infections vs none, beta = -0.14 and P < .001).

254 content in individual calf muscles in obese vs. normal healthy human subjects.

255 aMKII) phosphorylation of RyR2-S2814 residue vs. normoglycaemia.

256 an PFS vs those missing <8 days (10.9 months vs not reached).

257 PM status was significantly worse in younger vs older patients for thyroid, Hodgkin lymphoma, non-Hod

258 propensity score-matched analysis of robotic vs open pancreatoduodenectomy to date, and it demonstrat

259 PFS was improved with IRd vs placebo-Rd in both high-risk and standard-risk cytoge

260 in the placebo group (P<0.001 for each dose vs. placebo), and everyday-activities scores improved by

261 in the placebo group (P<0.001 for each dose vs. placebo).

262 sun exposure (for painful burn with blisters vs. practically no reaction, multivariable-adjusted RR =

263 CKD-RDN sheep (p < 0.0001 for 2 and 5 months vs. pre-RDN).

264 ory strategy, a greater focus on the future (vs. present), and a stronger focus on self-control.

265 2) reduction by chronoamperometry at -0.35V (vs pseudo-Ag/AgCl) using glucose oxidase immobilized on

266 hearing loss and hair color (for black hair vs. red or blonde hair, multivariable-adjusted relative

267 eye of origin) and dynamics (relatively slow vs. relatively fast).

268 that are differentially regulated in latent vs. replicative states of infection.

269 ally polarizing MoS2 at negative potentials (vs RHE) in acidic media or immersing MoS2 into certain a

270 ish vs. freshwaters), and nucleic acids (DNA vs. RNA), suggesting niche differentiation.

271 sampling (according to age, residence [urban vs rural], and sex) in all countries to recruit eligible

272 central, and eastern China], urbanity [urban vs rural], ethnic origin [Han and non-Han], occupation [

273 ity of quality-of-life improvement with TAVR vs SAVR in this population.

274 tality ratio in men aged 20-69 years in fast vs slow privatised towns: 1.13, SMR 0.83, 95% CI 0.77-0.

275 and ventral striatum, such that the normal (vs. slow) genotype individuals showed greater functional

276 macular functional impairment (RS decrease) vs SND-.

277 s with follow-up HSCT (inotuzumab ozogamicin vs standard care) was 1.227 (97.5% CI 0.656-2.292; one-s

278 effectiveness of pelvic physiotherapy (PPT) vs standard medical care (SMC) in children with FC.

279 fety and Effectiveness of Edoxaban (DU-176b) vs. Standard Practice of Dosing With Warfarin in Patient

280 -1) x g(-1), P < 0.01 vs. controls, P < 0.05 vs. standard-dose).

281 ative proportion of C lost to the atmosphere vs. stored or transported downstream.

282 s. 0.32 +/- 0.02 mum(2) , P = 0.197, Trained vs. T2DM).

283 ifference was seen between the placebo patch vs the 100-mug patch.

284 skin MC responses to FcepsilonRI triggering vs those evoked by MRGPRX2.

285 critical analysis of speeds of sound in ILs vs those in classical molecular solvents is presented to

286 e days of ibrutinib had a shorter median PFS vs those missing <8 days (10.9 months vs not reached).

287 stimated the probability of glaucoma control vs time postoperatively, and values were compared betwee

288 l (intravenous or intramuscular) ondansetron vs traditional therapy to resolve the symptoms of acute

289 [19%] of 195 patients in the olaparib group vs two [2%] of 99 patients in the placebo group), fatigu

290 cebo group), fatigue or asthenia (eight [4%] vs two [2%]), and neutropenia (ten [5%] vs four [4%]).

291 , or Fitzpatrick skin phototype (for type IV vs. type I, multivariable-adjusted RR = 0.99, 95% CI: 0.

292 t the hypothesis that muscles rich in type I vs. type II muscle fibers would exhibit similar changes

293 Decision confidence, consistency (primed vs unprimed), and quality (script concordance) were asse

294 incidence and thickness differed in screened vs unscreened patients.

295 y referrals, and patient outcomes in trained vs untrained PCPs are needed before screening is widely

296 th mean 66.9% (range, 42.0%-87.6%) reduction vs vehicle (P < .0001).

297 100, and VP250 groups, respectively (placebo vs VP100, P = .014; placebo vs VP250, P = .003).

298 ctively (placebo vs VP100, P = .014; placebo vs VP250, P = .003).

299 riptomes of tomato infected with X. gardneri vs. XgDeltaavrHah1 revealed the differential up-regulati

300 red in aged hearts during ischemia (P < 0.05 vs. young hearts).